期刊
REGENERATIVE MEDICINE
卷 16, 期 4, 页码 405-422出版社
FUTURE MEDICINE LTD
DOI: 10.2217/rme-2020-0169
关键词
chimeric antigen receptor T-cell therapy; health technology assessment; innovative payment mechanisms; market access; gene therapy; outcomes-based reimbursement
Innovative reimbursement mechanisms are increasingly used for gene therapies in Europe, while the usage is more limited in the USA. Decision makers in different countries face varying incentives and challenges in managing uncertainties around the long-term therapeutic potential of gene therapies.
Innovative reimbursement mechanisms have long been considered potential solutions to the data uncertainty associated with one-off, high-value gene therapies that have long-term therapeutic potential, combined with limited supporting evidence at launch. The launches of increasing numbers of such gene therapies in Europe and the USA in the past 5 years provide valuable exemplars of how innovative reimbursement mechanisms are used by healthcare system decision makers in practice. This review details the use of such reimbursement schemes for recently launched gene therapies in key European countries and the USA, and shows that they are more widespread in Europe than in the USA. Although innovative payment schemes are increasingly used across countries, differences in healthcare system structures (e.g., single- vs multi-payer systems) and willingness to pay mean that decision makers in different countries have different incentives to manage uncertainties around long-term, real-world product value.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据